Mergers and acquisitions of pharmaceutical companies reached $2112 trillion in the first half of the year.


Release time:

2015-07-28


In 2014, the scale of mergers and acquisitions in the biomedical industry far exceeded that in 2013. Among them, the total value of the top 10 mergers and acquisitions was nearly US $180 billion, which was almost three times the total value of US $66.4 billion in 2013. However, a recent report said that the record of 2014 may not be much before 2015.
According to the Mergermarket report, the total amount of mergers and acquisitions in the global pharmaceutical, medical and biotechnology industries reached US $2112 trillion in the first half of 2015, a record high since 2001 and an increase of 2.7 per cent from US $2057 trillion in 2014.
Among them, the pharmaceutical industry is the main force leading to this growth. So far this year there have been 168 deals totaling more than $159.1 billion. Compared with the data released in the same period last year, an increase of 58.6.
So, which companies have joined the wave of mergers and acquisitions? On January 11, Shire announced that it would buy NPS, an American rare disease drug manufacturer, for $5.2 billion. On February 5, Pfizer announced that it would buy US drug and medical device manufacturer Hospira Inc(HSP) for about US $17 billion. On May 18, Ireland-based pharmaceutical company Endo announced that it would acquire Par Pharmaceuticals in the form of shares and cash worth 8.05 billion US dollars.
However, it remains to be seen whether this M & A boom will continue in the second half of the year. Many pharmaceutical companies are now resisting offers on the grounds that their businesses are undervalued. However, their "suitors" may eventually "carry them home" by raising their offers ". Teva is one example.
On April 22, Israel Teva Pharmaceuticals, the world's largest generic drug manufacturer, proposed a merger with Mylan, the world's third-largest generic drug manufacturer, for $82 per share with a total transaction value of approximately $40.1 billion. However, for this price, Mylan is rejected. A few days ago, Teva made a new offer, increasing the maximum to $43 billion, or $86-88 per share.
In fact, for the acquisition in the first half of this year, the author's deepest impression is "Pfizer wants to acquire GSK for $146 billion?". The news came out and triggered a big guess in the industry. Not to mention the impact of the merger of the two giants on the pharmaceutical industry, this amount alone has a great impact on the acquisition record.